Clinical trials
Active, not recruiting Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2019 | 7 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 38 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Baylor College of Medicine | 4 |
| M.D. Anderson Cancer Center | 3 |
| Novartis Pharmaceuticals | 3 |
| Center for International Blood and Marrow Transplant Research | 2 |
| Poitiers University Hospital | 2 |
| St. Jude Children's Research Hospital | 2 |
| Centre Leon Berard | 1 |
| Children's Oncology Group | 1 |
| Dana-Farber Cancer Institute | 1 |
| European LeukemiaNet | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 38 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 |
| Myelodysplastic Syndromes | 16 |
| Leukemia, Myeloid, Acute | 14 |
| Lymphoma, Non-Hodgkin | 11 |
| Hodgkin Disease | 6 |
| Leukemia | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Lymphoproliferative Disorders | 5 |
| Myeloproliferative Disorders | 5 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.